Back to Search Start Over

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

Authors :
Stratigos, Alexander J
Garbe, Claus
Dessinioti, Clio
Lebbe, Celeste
Bataille, Veronique
Bastholt, Lars
Dreno, Brigitte
Fargnoli, Maria Concetta
Forsea, Ana Maria
Frenard, Cecille
Harwood, Catherine Α
Hauschild, Axel
Hoeller, Christoph
Kandolf-Sekulovic, Lidija
Kaufmann, R
Kelleners-Smeets, Nicole Wj
Malvehy, Josep
Del Marmol, Veronique
Middleton, Mark R
Moreno-Ramirez, David
Pellecani, Giovanni
Peris, Ketty
Saiag, Philippe
van den Beuken-van Everdingen, Marieke H J
Vieira, Ricardo
Zalaudek, Iris
Eggermont, Alexander M M
Grob, Jean-Jacques
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)
National and Kapodistrian University of Athens (NKUA)
Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen
Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976))
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
North & East Hertfordshire NHS Trust [Northwood, UK]
Odense University Hospital (OUH)
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA)
Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Centre d’Investigation Clinique de Nantes (CIC Nantes)
Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes)
University of L'Aquila [Italy] (UNIVAQ)
University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD)
Queen Mary University of London (QMUL)
Kiel University
Medizinische Universität Wien = Medical University of Vienna
Military Medical Academy [Belgrade, Serbia] (2MA)
Frankfurt University Hospital
Maastricht University Medical Centre (MUMC)
Maastricht University [Maastricht]
University of Barcelona
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Universitat de Barcelona (UB)
CIBER de Enfermedades Raras (CIBERER)
Instituto de Salud Carlos III [Madrid] (ISC)
Université libre de Bruxelles (ULB)
Hôpital Erasme [Bruxelles]
University of Oxford
Hospital Universitario Virgen Macarena [Sevilla, Spain] (HUVM)
University - Hospital of Modena and Reggio Emilia [Modena, Italy]
Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Istituto Neurologico Mediterraneo (NEUROMED I.R.C.C.S.)
Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA)-University of Naples Federico II = Università degli studi di Napoli Federico II
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay
Hôpital Ambroise Paré [AP-HP]
University Veterinary Hospital [Coimbra, Portugal]
Università degli studi di Trieste = University of Trieste
Princess Máxima Center for Pediatric Oncology
Assistance Publique - Hôpitaux de Marseille (APHM)
Aix Marseille Université (AMU)
Novartis Les Laboratories Pierre Fabre Sanofi Bristol-Myers Squibb, BMS Pfizer Amgen Roche LEO Pharma Research Foundation Cilag Merck Meso Scale Diagnostics, MSD Genentech
The guidelines were supported by grants from the EADO for the guideline meetings. The authors did this work on a voluntary basis and did not receive any honorarium or reimbursements. Guidelines development group members stated their conflicts of interest in the relevant section.
Dr. Stratigos reports personal fees and/or research support from Novartis , Roche , BMS , Abbvie , Sanofi , Regeneron , Genesis Pharma , outside the submitted work. Dr. Garbe reports personal fees from Amgen , personal fees from MSD , grants and personal fees from Novartis , grants and personal fees from NeraCare, grants and personal fees from BMS , personal fees from Pierre Fabre , personal fees from Philogen, grants and personal fees from Roche , grants and personal fees from Sanofi , outside the submitted work. Dr. Dessinioti has nothing to disclose. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb , personal fees from MSD , personal fees from Novartis , personal fees from Amgen , grants and personal fees from Roche , personal fees from Avantis Medical Systems, personal fees from Pierre Fabre , personal fees from Pfizer , personal fees from Incyte, outside the submitted work. Dr. Bataille reports personal fees from Novartis , personal fees from Merck MSD , outside the submitted work. Dr. Bastholt reports personal fees for advisory board activity: BMS , Roche , Novartis , Pierre-Fabre, Astra Zeneca, InCyte, MSD / Merck , Bayer . Dr. Dréno reports grants and personal fees from BMS , personal fees from MSD , grants and personal fees from Roche , grants and personal fees from Fabre, grants and personal fees from Sanofi , outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall, grants and personal fees from Leo Pharma, personal fees from Janssen, grants and personal fees from Novartis , personal fees from Lilly , grants and personal fees from Sanofi , personal fees from UCB , grants and personal fees from Abbvie , personal fees from Celgene , personal fees from Pierre Fabre , grants and personal fees from Galderma , personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche , personal fees from Sun Pharma , outside the submitted work. Dr. Forsea reports scientific consultant/speaker fee from Novartis , Leo Pharma, Solartium, Pierre-Fabre, outside the submitted work. Dr. Frenard has nothing to disclose. Dr. Harwood reports institutional research grants and honoraria from Sanofi , Novartis , Merck , Pfizer , Galderma , MEDA, Almirall, Pellepharm, Leo Pharma, CERIES. Dr. Hauschild reports honoraria and/or research grants from: Almirall, BMS , Roche , Novartis , Pierre-Fabre, Sunpharma, MerckSerono, SanofiAventis, Regeneron , MSD / Merck , Philogen, OncoSec outside the submitted work. Dr. Hoeller reports grants and personal fees from Amgen , personal fees from BMS , personal fees from MSD , personal fees from Novartis , personal fees from Pierre Fabre , personal fees from Roche , personal fees from Sanofi , personal fees from Incyte, outside the submitted work. Dr. Kandolf-Sekulovic reports speakers’ honoraria for Roche, Novartis, MSD, BMS, Janssen outside the submitted work. Dr. Kaufmann reports institutional research grants (clinical trials) from: AbbVie , Amgen , Biontech, BMS , Celgene , Galderma , Janssen, Leo, Lilly , Merck , MSD , Novartis , Pierre Fabre , Pfizer , Regeneron , Roche , Wyeth . Advisory Board and Honoraria from Merz, Roche, Novartis. Dr. Kelleners-Smeets reports grants from Netherlands Organization for Health Research and Development, other from Janssen-Cilag, other from AbbVie , other from Galderma , outside the submitted work. Dr. Malvehy reports research grants from Almirall, ISDIN, Leo Pharma, Galderma , GSK , Cantabria
participation in advisory board meetings for Almirall, Sunpharma, BMS , Roche , Novartis , Pierre-Fabre. Dr. del Marmol reports personal fees from MSD , from BMS , personal fees from Sanofi , grants and personal fees from ABVIE, grants from Jansen, outside the submitted work. Dr. Middleton reports personal fees and/or grants from Amgen , Roche , Astrazeneca, GSK , Novartis , Immunocore, BMS , Eisai and Merck . Institutional funding from Millennium, Vertex, Pfizer , Regeneron , TCBiopharma, BiolineRx, Replimune, outside the submitted work. Dr. Moreno-Ramírez has nothing to disclose. Dr. Pellecani reports grants from university of modena and reggio emilia, during the conduct of the study
grants from novartis, grants and personal fees from almirall, grants from leo pharma, from null, outside the submitted work. Dr. Peris reports honoraria for advisory board and grants from AbbVie , Almirall, Biogen Celgene , Lilly , Galderma , Leo Pharma, Novartis , Roche , Sanofi , Sun Pharma , Sandoz outside the submitted work. Dr. Saiag reports honoraria for advisory board and grants from Amgen , Bristol-Myers Squibb , MSD , Merck-Serono, Novartis , Pfizer , Roche- Genentech , Pierre Fabre , and Sanofi , outside the submitted work. Dr. van den Beuken-van Everdingen has nothing to disclose. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports honoraria and advisory board and grants from Sanofi , Sun Pharma , Novartis , Galderma , Roche , Celgene , Almirall, Leofarma, Mylan, Difa Cooper, Cieffe Labs, La Roche Posay, Pierre Fabre . Dr. Eggermont reports over the last 5 years personal fees as a consultant advisor for Biocad, BioInvent, Bristol Myers Squibb ( BMS ), CatalYm, Ellipses, Glaxo Smith Kline ( GSK ), HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, Merck Sharpe & Dohme ( MSD ), Novartis , Pfizer , Polynoma, Regeneron , Sanofi , Sellas, SkylineDx. Dr. Grob reports personal fees for advisory board and as speaker from Amgen , Roche , GSK , Novartis , BMS , Pierre fabre, Merck , Sanofi , Merck , Pfizer outside the submitted work.
European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)
HAL UVSQ, Équipe
Dermatologie
MUMC+: MA Dermatologie (9)
RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
RS: MHeNs - R3 - Neuroscience
MUMC+: TPZ Palliatieve Zorg (9)
Stratigos, A. J.
Garbe, C.
Dessinioti, C.
Lebbe, C.
Bataille, V.
Bastholt, L.
Dreno, B.
Fargnoli, M. C.
Forsea, A. M.
Frenard, C.
Harwood, C. Alpha.
Hauschild, A.
Hoeller, C.
Kandolf-Sekulovic, L.
Kaufmann, R.
Kelleners-Smeets, N. W.
Malvehy, J.
del Marmol, V.
Middleton, M. R.
Moreno-Ramirez, D.
Pellecani, G.
Peris, K.
Saiag, P.
van den Beuken-van Everdingen, M. H. J.
Vieira, R.
Zalaudek, I.
Eggermont, A. M. M.
Grob, J. -J.
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)
Source :
European Journal of Cancer, European Journal of Cancer, 2020, 128, pp.60-82. ⟨10.1016/j.ejca.2020.01.007⟩, European Journal of Cancer, 128, 60-82. ELSEVIER SCI LTD, European journal of cancer, 128, European Journal of Cancer, Elsevier, 2020, 128, pp.60-82. ⟨10.1016/j.ejca.2020.01.007⟩, European Dermatology Forum (EDF), European Association of Dermato-Oncology (EADO), European Organization for Research and Treatment of Cancer (EORTC) 2020, ' European interdisciplinary guideline on invasive squamous cell carcinoma of the skin : Part 1. epidemiology, diagnostics and prevention ', European Journal of Cancer, vol. 128, pp. 60-82 . https://doi.org/10.1016/j.ejca.2020.01.007
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated in cSCC etiopathogenesis include ultraviolet radiation exposure and chronic photoaging, age, male sex, immunosuppression, smoking and genetic factors. A collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation of Research and Treatment of Cancer (EORTC) was formed to update recommendations on cSCC classification, diagnosis, risk stratification, staging and prevention, based on current literature, staging systems and expert consensus. Common cSCCs are typically indolent tumors, and most have a good prognosis with 5-year cure rates of greater than 90%, and a low rate of metastases (<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Subjects

Subjects :
0301 basic medicine
Cancer Research
Skin Neoplasms
Staging
Medical Oncology
Palpation
Imaging
Low-risk
0302 clinical medicine
Protective Clothing
Metastatic cSCC
Positron Emission Tomography Computed Tomography
Diagnosis
Epidemiology
Societies, Medical
AMERICAN JOINT COMMITTEE
Skin
Ultrasonography
Invasive cutaneous squamous cell carcinoma
medicine.diagnostic_test
NONSTEROIDAL ANTIINFLAMMATORY DRUGS
High-risk common primary cSCC
RANDOMIZED CONTROLLED-TRIAL
Prognosis
Magnetic Resonance Imaging
3. Good health
LYMPH-NODE BIOPSY
Oncology
030220 oncology & carcinogenesis
Carcinoma, Squamous Cell
Sunlight
Settore MED/35 - MALATTIE CUTANEE E VENEREE
Diagnosi
medicine.medical_specialty
Consensus
Prognosi
Sentinel lymph node
Locally advanced Cscc
Prevention
Dermatology
Humans
Lymph Nodes
Neoplasm Staging
Patient Education as Topic
Risk Assessment
Sunscreening Agents
[SDV.CAN]Life Sciences [q-bio]/Cancer
Physical examination
PERINEURAL INVASION
03 medical and health sciences
BASAL-CELL
[SDV.CAN] Life Sciences [q-bio]/Cancer
Medical
Biopsy
medicine
CANCER PREVENTION
ORGAN TRANSPLANT RECIPIENTS
business.industry
Carcinoma
Cancer
Magnetic resonance imaging
Guideline
medicine.disease
Cancérologie
HIGH-RISK
030104 developmental biology
Squamous Cell
SUN PROTECTION
Societies
business

Details

ISSN :
09598049
Volume :
128
Database :
OpenAIRE
Journal :
European Journal of Cancer
Accession number :
edsair.doi.dedup.....73017e8d64a0e3566ed10f8a2e527bad
Full Text :
https://doi.org/10.1016/j.ejca.2020.01.007
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details